King & Wood Mallesons advised Cerba European Lab on the acquisition of Novescia. The transaction is expected to close in the first quarter of 2015.

Cerba European Lab is a clinical pathology group active in all three sections of the market: routine clinical pathology, specialist clinical pathology and clinical trial pathology. Cerba European Lab comprises a network of 200 laboratories and over 150 sampling centres located primarily in France, as well as elsewhere in Europe and in the United States, South Africa, Australia and China.

Novescia is one of France's leading medical biology groups. In 2014, Novescia generated a turnover of €150 million.

The King & Wood Mallesons team was composed of Corporate partners Maxence Bloch and William Robert, and associates Thomas Dupont-Sentilles, Imen Moustafid, Chloé Vu Thien and Aurélien Diday, as well as Finance partner Raphael Béra and associate Thomas Guillier, and Real Estate associate Géraldine Palais.